Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon May 25, 2024 8:51pm
108 Views
Post# 36057695

RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionFor tthose traders who are trying to exploit the BRACELET-1 cohort 3 results by implying something that is not .. cohort 3 involved the immune checkpoint inhibitor avelumab which is the only PD-(L)1 inhibitor with an intact Fc component, thus precluding this ICI's effectiveness. Other ICIs like atezolizumab or pembrolizumab, foe example, have the Fc component inactived, and more effective than avelumab. In contrast to cohort 3, cohort 2 using  pelareorep + paclitaxel significantly expanded on pre-existing and new T cell clones, and will be the doublet used in ONCY's  registrational brest cancer study. So no worries ... ONCY is demonstrating that pelareorep is an effective agent in the pelareorep + paclitaxel  combo when compared to the control, namely paclitaxel alone.
<< Previous
Bullboard Posts
Next >>